31 matches for your search in the start-up spotlight
rss
Successfully birthed an extinct species
10-Apr-2025
Colossal Biosciences, the world’s only de-extinction company, announces the rebirth of the once extinct dire wolf, the world’s first successfully de-extincted animal. The dire wolf, largely assumed to be a legendary creature made famous from the HBO hit series Game of Thrones, was an American ...
Colossal Secures $200M in Series C Funding From TWG Global
21-Jan-2025
Colossal Biosciences, the world’s first de-extinction company, has announced $200M in a Series C financing by TWG Global, a diversified holding company with operating businesses and investments in technology/AI, financial services, private lending and sports and media, jointly led by Mark Walter ...
International team of scientists and start-up Colossal Biosciences decode the DNA of the bluebuck using state-of-the-art computer analysis software
17-Apr-2024
An international team of researchers led by the University of Potsdam has generated and analyzed the first high-coverage nuclear genome of the extinct blue antelope in cooperation with Colossal Biosciences and the Museum of Natural History Berlin. The genomic data shed light on the evolutionary ...
Start-up aims to make sustainable coral farming commercially viable and boost the protection of wild corals
10-Apr-2024
Coral farming based on sexual propagation, leading to a more sustainable coral trade and helping to protect coral reefs – this is the goal of SciReef, a new start-up which is emerging from a research transfer project. SciReef is based on the research conducted by Dr Samuel Nietzer and Dr Mareen ...
Cyberagentur finances revolution in neuro-adaptive human-machine interaction
09-Jan-2024
On 15 December 2023, the Agentur für Innovation in der Cybersicherheit GmbH (Cyberagentur) signed a contract worth 30 million euros with the Cottbus-based startup Zander Laboratories GmbH. The company will develop neurotechnological prototypes over the next four years to revolutionise ...
£4 million investment sets path for commercialisation of groundbreaking cell analysis technology
25-Sep-2023
The biotech company’s appointment of industry leader Dr Sharon Brownlow as Non-Executive Director further enhances Cytomos’ senior management team and its unique value proposition to key industry markets. Dr Brownlow will play a key role in helping to accelerate Cytomos’ plansto commercialise ...
Colossal will assist the rescue mission by leveraging genome sequencing and gene editing methods to save the endangered species
22-Sep-2023
With only two living females left, the partnership will contribute to the genetic recovery of the northern white rhino from complete extinction. Colossal developed a pioneering toolkit for the challenging task to restore genetic diversity from museal specimens for a living population of ...
Spin-off company pinpoints the best time to exercise, sleep and take medicine
24-May-2023
An interdisciplinary team led by Prof. Angelo Relógio, a scientist at Charité’s Molecular Cancer Research Center (MKFZ) and Institute for Theoretical Biology and the MSH Medical School Hamburg, has developed a non-invasive method for profiling a person’s unique circadian rhythm. Starting with a ...
INCATE catalyzes critical growth stage at Invitris
11-May-2023
INCATE has selected Invitris as the first venture to receive €250,000 in “Stage II Funding” that will allow Invitris to complete spin-out from Chair of Physics of Synthetic Biological Systems at the Technical University of Munich (TUM) and further its mission to scale the production of phages, ...
New platform has potential to fuel advances in senolytic anti-aging compounds and longevity research
09-May-2023
Anew publicationin the May issue ofNature Agingby researchers from Integrated Biosciences, a biotechnology start-up company combining synthetic biology and machine learning to target aging, demonstrates the power of artificial intelligence (AI) to discover novel senolytic compounds, a class ...
